Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5155253 | 0.92 | PLA2G2A (0.47) | PLA2G2AKMT2ANR1H4DRD2TP53 | |
| SCHEMBL3854271 | 0.86 | HCAR3 (0.44) | PLA2G2AKMT2ARAB9AHCAR3MEN1 | |
| SCHEMBL17109507 | 0.84 | PLA2G2A (0.71) | PLA2G2AKMT2ANR1H4TP53TSHR | |
| SCHEMBL3853305 | 0.82 | KMT2A (0.44) | PLA2G2AKMT2AHCAR3RARB | |
| SCHEMBL23352165 | 0.81 | PLA2G2A (0.77) | PLA2G2AKMT2ANR1H4TP53TSHR | |
| SCHEMBL3853571 | 0.81 | HTT (0.40) | PLA2G2AKMT2ATSHRHCAR3 | |
| SCHEMBL3855652 | 0.80 | HCAR3 (0.40) | PLA2G2AKMT2ARAB9AHCAR3MEN1 | |
| SCHEMBL13306259 | 0.80 | TPMT (0.52) | KMT2ARAB9AHCAR3MEN1 | |
| SCHEMBL3854441 | 0.79 | TPMT (0.50) | KMT2ARAB9AHCAR3MEN1 | |
| SCHEMBL3860120 | 0.79 | TPMT (0.40) | PLA2G2AKMT2ARAB9AHCAR3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618978-B2 | Amides as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-7585885-B2 | Pyrrolidine derivatives useful as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| US-20070225372-A1 | Amides as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| US-20070213331-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS | ELI LILLY AND COMPANY | 2007-09-13 | — | — | US | disclosed |
| EP-1740573-A1 | AMIDES AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1740575-A2 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005108391-A1 | AMIDES AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108358-A2 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225372-A1 | Amides as Bace Inhibitors | BACE2, BACE1, APP | PLA2G2A 3061/4885KMT2A 619/4885NR1H4 1354/4885 |
| US-20070213331-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS | BACE1, BACE2, PSEN1 | PLA2G2A 3456/4885KMT2A 2934/4885NR1H4 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.